After three years since announcing his initial diagnosis, San Francisco Symphony Music Director Laureate Michael Tilson ...

近期， 浙江省人民医院神经外科胡韶山研究团队在 《Nature communications》（IF：14.7/Q1 TOP）发表了题为《Turning attention to tumor-host interface and focus on ...

Glioblastoma is the most aggressive and most common malignant brain cancer in adults. It is currently treated with surgery, ...

A keen runner who collapsed on a “normal day” and woke up bruised all over has been diagnosed with a devastating terminal ...

2025年2月19日，中国科学院生物物理研究所范克龙和阎锡蕴团队在《Science Advances》期刊上发表题为"Bioengineered protein nanocarrier facilitating siRNA escape from lysosomes for targeted RNAi therapy in ...

The research on glioblastoma requires the development of new preclinical murine models. The GL261 cell line forms glioma-like tumors in a reliable manner when transplanted intracranially, but these ...

HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a ...

Furthermore, they have demonstrated that it is possible to reprogram other cancer cells to become dependent on this enzyme – ...

Clinical research by Dana-Farber scientists suggests that combining a novel agent called navtemadlin with DNA-damaging chemotherapy for the treatment of glioblastoma, a form of brain cancer, could ...

The market for PDTs in oncology is projected to experience substantial growth in the coming years. This growth is driven by a rising number of patients diagnosed with conditions such as NMSCs, ovarian ...

CNS Pharmaceuticals (CNSP) will present at the 6th Glioblastoma Drug Development Summit being held February 18-20, 2025 in Boston, MA. As part ...

About the 6th Glioblastoma Drug Development Summit The 6th Glioblastoma Drug Development Summit is the only industry-led event bringing together 90+ experts from pharma, biotech, neuro-oncology ...